Stapled peptide-based radiotheranostics for intracellular protein-protein interactions targeted cancer imaging and therapy
| Project/Area Number |
21H02873
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 52040:Radiological sciences-related
|
|---|
| Research Institution | National Institutes for Quantum Science and Technology |
|---|
Principal Investigator |
胡 寛 国立研究開発法人量子科学技術研究開発機構, 量子医科学研究所 先進核医学基盤研究部, 研究員 (00827678)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
謝 琳 国立研究開発法人量子科学技術研究開発機構, 量子医科学研究所 先進核医学基盤研究部, 主任研究員 (30623558)
破入 正行 国立研究開発法人量子科学技術研究開発機構, 量子医科学研究所 先進核医学基盤研究部, 主任研究員 (80435552)
張 明栄 国立研究開発法人量子科学技術研究開発機構, 量子医科学研究所 先進核医学基盤研究部, 部長 (80443076)
|
|---|
| Project Period (FY) |
2021-04-01 – 2025-03-31
|
| Project Status |
Declined (Fiscal Year 2022)
|
| Budget Amount *help |
¥16,640,000 (Direct Cost: ¥12,800,000、Indirect Cost: ¥3,840,000)
Fiscal Year 2022: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2021: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
|
|---|
| Keywords | stapled peptide / radiotheranostics / intracellular protein / cancer / 64Cu / radionuclide therapy / intracellular delivery / PET imaging |
|---|
| Outline of Research at the Start |
A new kind of peptide-based radiotheranostics will be developed, denoted as stapled peptide-based radiotheranostics. They can reach the cancerous cells' plasma even the cell nucleus, and release radiation particles to destroy the DNA and RNA. Therefore, the cancerous cells can be eliminated.
|
| Outline of Annual Research Achievements |
This research project aims at the development of stapled peptide-based radiotheranostics for targeting intracellular protein protein interactions. In the past fiscal year, I developed a stapled peptide based, 64Cu labeled radiotheranostics, which can specifically bind to hDM2 in various cancer cells. The radiotheranostics, [64Cu]STP08, showed high tumor accumulation and retention in several animal models.More importantly, it significantly delayed tumor growth in mouse models and the efficacy is independent to the p53 phenotype.Biosafety study suggested that [64Cu]STP08 showed satisfactory and caused no hemotological and organ lesions in normal mice.
Moreover, we have successfully labelled STP with 225Ac, an alpha particle emitting radionuclide. The [225Ac]STP08 showed excellent treatment efficacy.
|
| Research Progress Status |
翌年度、交付申請を辞退するため、記入しない。
|
| Strategy for Future Research Activity |
翌年度、交付申請を辞退するため、記入しない。
|
Report
(1 results)
Research Products
(13 results)
-
-
-
-
-
[Journal Article] Whole-body PET tracking of a D-dodecapeptide and its radiotheranostic potential for PD-L1 overexpressing tumors2022
Author(s)
Hu Kuan, Wu Wenyu, Xie Lin, Geng Hao, Zhang Yiding, Hanyu Masayuki, Zhang Lulu, Liu Yinghuan, Nagatsu Kotaro, Suzuki Hisashi, Guo Jialin, Wu Yundong, Li Zigang, Wang Feng, Zhang Ming-Rong
-
Journal Title
Acta Pharmaceutica Sinica B
Volume: 12
Issue: 3
Pages: 1363-1376
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
-
-
-
-
-
